ArticleOncogene2004
Melanoma cells secrete follistatin, an antagonist of activin-mediated growth inhibition.
Article in Oncogene, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 43 citations in OpenAlex.
- The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells.PloS one · 2014Trial
- Kallikrein-8 mediates furin-independent Activin-A precursor processing to stimulate tumor growth in melanoma.Nature communications · 2025Article
- Stepwise release of Activin-A from its inhibitory prodomain is modulated by cysteines and requires furin coexpression to promote melanoma growth.Communications biology · 2024Article
- The Reign of Follistatin in Tumors and Their Microenvironment: Implications for Drug Resistance.Biology · 2024Review
- TAK1 suppresses RIPK1-dependent cell death and is associated with disease progression in melanoma.Cell death and differentiation · 2019Article
- Follistatin impacts Tumor Angiogenesis and Outcome in Thymic Epithelial Tumors.Scientific reports · 2019Article
- SMAD signaling promotes melanoma metastasis independently of phenotype switching.The Journal of clinical investigation · 2019Article
- High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma.Oncotarget · 2016Article
- Comparative proteomic analysis reveals unique tumor protein composition among the melanoma subtypes pure desmoplastic and superficial spreading.Melanoma research · 2014Article
- Follistatin as potential therapeutic target in prostate cancer.Targeted oncology · 2013Review
- Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells.British journal of cancer · 2012Article
- A pair of transmembrane receptors essential for the retention and pigmentation of hair.Genesis (New York, N.Y. : 2000) · 2012Article
- Non-canonical Smads phosphorylation induced by the glutamate release inhibitor, riluzole, through GSK3 activation in melanoma.PloS one · 2012Article
- Serum follistatin in patients with prostate cancer metastatic to the bone.Clinical & experimental metastasis · 2010Article
- Identification of proteins involved in neural progenitor cell targeting of gliomas.BMC cancer · 2009Article
- Induction of follistatin precedes gastric transformation in gastrin deficient mice.Biochemical and biophysical research communications · 2008Article
- Peroxisome proliferator-activated receptor gamma down-regulates follistatin in intestinal epithelial cells through SP1.The Journal of biological chemistry · 2008Article
- Activins and activin antagonists in hepatocellular carcinoma.World journal of gastroenterology · 2008Review
- Transcriptional profile of Rous Sarcoma Virus transformed chicken embryo fibroblasts reveals new signaling targets of viral-src.Virology · 2007Article
- Clinical and Therapeutic Implications of Follistatin in Solid Tumours.Cancer genomics & proteomicsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Using a proteomic approach to screen for new growth factors released by melanoma cells, we identified follistatin as a major heparin-binding factor in medium conditioned by the Bowes melanoma cell line. Since follistatin is primarily studied in relation to its neutralization of activin, a member of the transforming growth factor-beta family of ligands, the expression and function of this receptor system was investigated in a panel of melanoma cell lines and melanocytes. All cell lines expressed activin receptors and showed phosphorylation of Smad signal transduction molecules upon treatment with activin. Secretion of follistatin, either native or after retroviral transduction, efficiently prevented Smad activation or activation of an activin-responsive luciferase reporter construct. In melanocytes, activin treatment led to growth inhibition and induction of apoptosis. These effects were counteracted by cotreatment with follistatin. In summary, we characterized the activin-activin receptor system in melanocytes and melanoma cell lines and found that secretion of follistatin by melanoma cells may represent an effective way to circumvent activin's negative regulatory effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.